Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for recovery after elective craniotomy
IRCT20210222050463N7Phase 3Recruiting
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jul 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, double-blind trial of Sugammadex, neostigmine and glycopyrronium in brain neoplasm (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: Quality of Recovery-40 score at 24 hours postoperatively. Started Jul 2026; status: recruiting.
02
Drugs
Sugammadexneostigmineglycopyrronium
03
Conditions
brain neoplasm
Beyond the preview
Go deeper on IRCT20210222050463N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210222050463N7.